Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study
Transfusion · 2023
DOI: 10.1111/trf.17382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2023. Verfasst von Rika A Furuta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Hepatitis B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
In Japan, plasma with a high concentration of Hepatitis B Virus (HBV) antibodies for hepatitis B immunoglobulin (HBIG) is almost entirely imported. We aimed to produce recombinant HBIG by isolating immunoglobulin cDNAs against the HBV surface antigen (HBsAg). Study Design and Methods B cells expressing HBsAg antibodies were obtained from blood center personnel who had been administered HB vaccine booster and then isolated by either an Epstein–Barr virus hybridoma or an antigen‐specific memory B cell sorting method. Each cDNA of the heavy and light chains of the target antibody was cloned into an IgG 1 expression vector and transfected into Expi293F cells to produce a recombinant monoclonal antibody (mAb), which was screened by ELISA and in vitro HBV neutralizing assays. The cross‐reactivity of the mAbs to normal human molecules was evaluated by ELISA and immunohistochemistry.
Results
Antibody cDNAs were cloned from 11 hybridoma cell lines and 204 HBsAg‐bound memory B cells. Three of the resulting recombinant mAbs showed stronger neutralizing activity in vitro than the currently used HBIG. All three bind to the conformational epitope(s) of HBsAg but not to human DNA or cells.
Discussion
We successfully isolated HBV‐neutralizing monoclonal antibodies from B cells collected from healthy plasma donors boosted against the HBV. To obtain an alternative source for HBIG, HBV‐neutralizing monoclonal antibodies from B cells collected from healthy plasma donors boosted against the HBV may be useful.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
- Laboratory of Infectious Diseases and Immunity, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
- Toyama Prefectural Institute for Pharmaceutical Research, Toyama, Japan.
- Laboratory of Pharmacokinetic Optimization, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
- Laboratory of Biopharmaceutical Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
- Japanese Red Cross Kanto-Koushinetsu Block Blood Center, Tokyo, Japan.
ORCID-Profile: Rika A Furuta, Kazuta Yasui, Masahiro Satake
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Furuta, R. A., Yasui, T., Minamitani, T., Akiba, H., Toyoda, C., Tobita, R., Yasui, K., Aminaka, R., Masaki, M., & Satake, M. (2023). Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study. Transfusion. https://doi.org/10.1111/trf.17382
Vancouver
Furuta RA, Yasui T, Minamitani T, Akiba H, Toyoda C, Tobita R, et al. Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study. Transfusion. 2023. doi:10.1111/trf.17382
BibTeX
@article{Furuta2023,
author = {Furuta, Rika A and Yasui, Teruhito and Minamitani, Takeharu and Akiba, Hiroki and Toyoda, Chizu and Tobita, Ryutaro and Yasui, Kazuta and Aminaka, Ryota and Masaki, Mikako and Satake, Masahiro},
title = {Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study},
journal = {Transfusion},
year = {2023},
doi = {10.1111/trf.17382}
}
EUVIMED